Technology and healthcare companies are continuing to dominate the IPO market, which is witnessing a significant increase in activity compared to 2023.
Alumis looks to raise $300 million in IPO. Here’s what you need to know
Categories
pharma stocks
Ocean Biomedical co-founder Jack Elias to receive US patent for pulmonary fibrosis treatments
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Abbott Laboratories (ABT) Q1 2022 Infographic: Key financials and quarterly highlights
Abbott (NYSE: ABT) today reported its first-quarter financial results for the period ended March 31, 2022. GAAP net earnings for the first
Johnson & Johnson (JNJ) reports Q1 2022 earnings
Johnson & Johnson (NYSE: JNJ) reported first-quarter 2022 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue
Eli Lilly and Company (LLY) Earnings: 4Q21 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported revenue of $7.9 billion for the fourth quarter of 2021, up 8% year-over-year. Reported net
BMY Earnings: Key quarterly highlights from Bristol-Myers Squibb Q3 financial results
Bristol-Myers Squibb Company (NYSE: BMY) reported second-quarter 2021 earnings. Revenues increased 10% year-over-year to $11.6 billion. Net earnings attributable to Bristol Myers
Infographic: Highlights of Gilead Sciences (GILD) Q2 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its second-quarter 2021 earnings today after the closing bell. The revenue increased by 21%
Infographic: Highlights of Merck & Co. (MRK)Q2 2021 earnings report
Merck & Co., Inc. (NYSE: MRK) reported earnings and sales for the second quarter of 2021. Worldwide sales edged up 22% year-over-year
Context Therapeutics: Another clinical-stage oncology research firm to go public soon
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first
Infographic: Highlights of Gilead Sciences (GILD) Q1 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its first-quarter 2021 earnings today after the closing bell. The revenue increased by 16%
Infographic: Teva Pharmaceuticals (TEVA) Q1 2021 earnings results
Teva Pharmaceuticals’ (NYSE: TEVA) reported first-quarter 2021 results today before the opening bell. The company dropped its revenue by 9% to $3.98
Johnson & Johnson (JNJ) reports Q1 2021 earnings
Johnson & Johnson (NYSE: JNJ) reported first-quarter 2021 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue
ABT Earnings: Key numbers from Abbott Laboratories Q4 financial results
Abbott (NYSE: ABT) today announced its fourth-quarter financial results for the period ended December 31, 2020. Net earnings for the fourth quarter
ImmunoGen Inc (IMGN): Q4 2019 Earnings Snapshot
— ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected. — Revenue jumped
Regeneron Pharmaceuticals (REGN): Q4 2019 Earnings Snapshot
-- Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected. -- Revenues grew 13% to $2.17
Where does Merck (MRK) stand in the cancer-drug race?
Shares of Merck and Co. (NYSE: MRK) this week pared some of their recent gains even as the ex-dividend date approaches. While
Vertex Pharmaceuticals (VRTX): Q3 2019 Earnings Snapshot
-- Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected -- Total revenue grew
Amgen beats in Q3, raises guidance
Amgen Inc (NASDAQ: AMGN) reported third-quarter 2019 adjusted EPS of $3.66 on revenue of $5.74 billion. This was better than analysts’ prediction
AbbVie wins FDA approval for Rinvoq, stock gains
Shares of biopharmaceutical firm AbbVie (NYSE: ABBV) jumped 2.1% after the company received approval from the US Food and Drug Administration for
Intercept Pharmaceuticals beats in Q2, keeps full-year outlook unchanged
Intercept Pharmaceuticals (NASDAQ: ICPT) on Wednesday reported second-quarter results that surpassed Wall Street expectations, riding on the strong growth of its liver
Bausch Health stock rises on guidance hike
Bausch Health Companies Inc. (NYSE: BHC) said its revenues for the second quarter edged up 1% to $2.15 billion, in line with